TY - JOUR
T1 - Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia
T2 - A randomized, placebo-controlled trial
AU - Resnick, M. I.
AU - Roehrborn, Claus
PY - 2007/5
Y1 - 2007/5
N2 - This randomized, double-blind, placebo-controlled study was conducted to investigate whether alfuzosin 10 mg once daily improves the maximum flow rate (Qmax) and lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH) after 1 week and 1 month of treatment. A total of 372 men aged ≥50 years with symptomatic BPH received alfuzosin or placebo for 28 days. Qmax increased significantly from baseline at day 8 with alfuzosin (P<0.001 versus placebo); this improvement was evident within 24 h after the first dose and was maintained at day 29. LUTS improved from baseline with alfuzosin at day 8 (P=0.07 versus placebo) and day 29 (P=0.003 versus placebo). Alfuzosin 10 mg once daily exhibits a rapid onset of action, with improvements in Qmax and LUTS maintained through 1 month of treatment.
AB - This randomized, double-blind, placebo-controlled study was conducted to investigate whether alfuzosin 10 mg once daily improves the maximum flow rate (Qmax) and lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH) after 1 week and 1 month of treatment. A total of 372 men aged ≥50 years with symptomatic BPH received alfuzosin or placebo for 28 days. Qmax increased significantly from baseline at day 8 with alfuzosin (P<0.001 versus placebo); this improvement was evident within 24 h after the first dose and was maintained at day 29. LUTS improved from baseline with alfuzosin at day 8 (P=0.07 versus placebo) and day 29 (P=0.003 versus placebo). Alfuzosin 10 mg once daily exhibits a rapid onset of action, with improvements in Qmax and LUTS maintained through 1 month of treatment.
UR - http://www.scopus.com/inward/record.url?scp=34249977256&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249977256&partnerID=8YFLogxK
U2 - 10.1038/sj.pcan.4500925
DO - 10.1038/sj.pcan.4500925
M3 - Article
C2 - 17211442
AN - SCOPUS:34249977256
SN - 1365-7852
VL - 10
SP - 155
EP - 159
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
IS - 2
ER -